<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04517786</url>
  </required_header>
  <id_info>
    <org_study_id>ISM10</org_study_id>
    <nct_id>NCT04517786</nct_id>
  </id_info>
  <brief_title>MINIject (MINI SO627) in Patients With Open Angle Glaucoma Using Single Operator Delivery Tool</brief_title>
  <official_title>A Prospective, Open, Clinical Trial Analysing The Efficacy and Safety of MINIJECT (MINI SO627) In Patients With Open Angle Glaucoma Uncontrolled By Topical Hypotensive Medications Using A Single Operator Delivery Tool</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iSTAR Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International Drug Development Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>iSTAR Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will assess safety and performance in patients with open-angle glaucoma&#xD;
      uncontrolled by topical hypotensive medications who had previously been implanted with a&#xD;
      MINIject glaucoma implant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will evaluate the efficacy and safety of MINI SO627 and IOP (Intra- ocular&#xD;
      pressure) lowering effects with or without the use of glaucoma medications. The procedure&#xD;
      will be a stand alone surgery. Patient follow up with several examinations up to 24 months&#xD;
      after surgery.&#xD;
&#xD;
      The primary endpoint is the reduction in medicated mean diurnal IOP at 6 months follow up&#xD;
      compared to medicated diurnal IOP at baseline visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>MINIject SO627</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in medicated or unmedicated (without washout) mean diurnal IOP at 6 months follow-up</measure>
    <time_frame>6 month post surgey</time_frame>
    <description>The primary endpoint of the study is the reduction in medicated or unmedicated (without washout) mean diurnal IOP at 6 months follow-up compared to medicated or unmedicated (without washout) diurnal IOP at baseline visit.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Glaucoma, Open-Angle Glaucoma Eye</condition>
  <arm_group>
    <arm_group_label>MINIject CS627 implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MINIject 627 implant is used to reduce intra-ocular pressure in the eye. It is implanted through a minimally-invasive glaucoma surgical intervention in a stand alone procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MINIject CS627 implant</intervention_name>
    <description>MINI SO627 is an integrated system comprising a minimally-invasive Glaucoma Drainage Implant (CS627) and a single operator delivery tool.&#xD;
The delivery tool is a single-use tool, designed for inserting the CS627 implant into the suprachoroidal space in the eye.</description>
    <arm_group_label>MINIject CS627 implant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of primary or secondary open angle glaucoma during screening/baseline visit&#xD;
             or earlier.&#xD;
&#xD;
          -  Grade 3 or grade 4 according to Shaffer Angle Grading System.&#xD;
&#xD;
          -  Glaucoma not adequately controlled by one to four different topical hypotensive&#xD;
             medication(s), given each for at least one month, as confirmed by 21mmHg &lt; IOP &lt; 35&#xD;
             mmHg in the study eye at baseline visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Grade 2 (narrow, 20 degrees), grade 1 (extremely narrow, less or equal to 10 degrees)&#xD;
             and grade 0 (closed or slit) according to Shaffer Angle Grading System in the study&#xD;
             eye.&#xD;
&#xD;
          -  Neovascular glaucoma in the study eye.&#xD;
&#xD;
          -  Corneal opacity or iridocorneal angle not visible through gonioprism in the study eye,&#xD;
             preventing correct placement of the implant in the stud eye.&#xD;
&#xD;
          -  Prior glaucoma surgery in the study eye.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zubair Hussain, PhD</last_name>
    <role>Study Director</role>
    <affiliation>iSTAR</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ljubomir Manola, PhD</last_name>
    <phone>+32 107 716 77</phone>
    <email>ljubomir.manola@istarmed.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pascale Ducloux</last_name>
    <phone>+32 107 716 76</phone>
    <email>pascale.ducloux@istarmed.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maxivision Super Speciality Eye Hospital</name>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kasu Prasad Reddy, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Panama Eye Center</name>
      <address>
        <city>Panam√°</city>
        <country>Panama</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ernesto Calvo, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
    <country>Panama</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 14, 2020</study_first_submitted>
  <study_first_submitted_qc>August 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2020</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glaucoma</keyword>
  <keyword>Medical device</keyword>
  <keyword>MIGS drainage device</keyword>
  <keyword>eye reduction IOP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

